Compugen Management
Management criteria checks 4/4
Compugen's CEO is Eran Ophir, appointed in Mar 2020, has a tenure of less than a year. total yearly compensation is $478.22K, comprised of 42.1% salary and 57.9% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth $23.60K. The average tenure of the management team and the board of directors is 2 years and 8.4 years respectively.
Key information
Eran Ophir
Chief executive officer
US$478.2k
Total compensation
| CEO salary percentage | 42.05% |
| CEO tenure | 6yrs |
| CEO ownership | 0.01% |
| Management average tenure | 2yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
Ovarian Trial Delays And Royalty Uncertainty Will Test This Long Runway Story
Catalysts About Compugen Compugen is a clinical stage immuno oncology company that uses a computational discovery engine to develop antibody based cancer therapies and out license assets to larger partners. What are the underlying business or industry changes driving this perspective?There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise
Oct 07
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Oct 02Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically
May 25Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation?
Apr 09Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet
Feb 26
COM701 Trial Will Present Future Opportunities, But Competitive Risks Remain
Strategic advancements in drug development and partnerships could significantly bolster earnings and create opportunities in less competitive markets.Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
Aug 22Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
May 22Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
May 01Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$35m |
| Sep 30 2025 | n/a | n/a | -US$28m |
| Jun 30 2025 | n/a | n/a | -US$19m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$478k | US$201k | -US$14m |
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$541k | US$196k | -US$19m |
Compensation vs Market: Eran's total compensation ($USD478.22K) is below average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: Eran's compensation has been consistent with company performance over the past year.
CEO
Eran Ophir (47 yo)
Dr. Eran Ophir is CEO, President & Director of Compugen Ltd. from September 2025. Dr. Ophir was Senior Vice President of Research & Drug Discovery of Compugen Ltd.from March 2022 to 2023. Dr. Ophir was Vi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | 12.1yrs | US$1.24m | 0.11% $ 225.4k | |
| CEO, President & Director | 6yrs | US$478.22k | 0.012% $ 23.6k | |
| Chief Operating Officer | 1.2yrs | US$604.00k | no data | |
| Senior Vice President of Business Development | 8.2yrs | US$461.80k | 0.031% $ 61.0k | |
| Chief Medical Officer | 2yrs | US$592.99k | 0.024% $ 48.0k | |
| Chief Financial Officer | 1.6yrs | no data | 0.038% $ 73.7k | |
| General Counsel & Corporate Secretary | 7.2yrs | no data | no data | |
| Vice President of Human Resources | 19.2yrs | no data | no data | |
| Vice President Research and Discovery | no data | no data | no data | |
| Senior Vice President of Research & Discovery | less than a year | no data | 0.021% $ 40.5k |
Experienced Management: CGEN's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | 12.1yrs | US$1.24m | 0.11% $ 225.4k | |
| CEO, President & Director | less than a year | US$478.22k | 0.012% $ 23.6k | |
| Member of Scientific Advisory Board | 5.5yrs | no data | no data | |
| Independent Director | 7.8yrs | no data | 0.013% $ 26.3k | |
| Member of Scientific Advisory Board | 12.6yrs | no data | no data | |
| Independent Director | 7.8yrs | no data | 0.012% $ 23.7k | |
| Independent Director | 7.8yrs | no data | 0.014% $ 27.7k | |
| Chairman of Scientific Advisory Board | 12.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 12.6yrs | no data | no data | |
| Independent Director | 6.7yrs | no data | 0.011% $ 20.8k | |
| Member of Scientific Advisory Board | 12.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 9yrs | no data | no data |
Experienced Board: CGEN's board of directors are considered experienced (8.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 15:49 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Compugen Ltd. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Wang | Chardan Capital Markets, LLC |
| Michael King | Citizens JMP Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |